Ligand Pharmaceuticals Incorporated (LGNYZ)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ligand Pharmaceuticals Incorporated (LGNYZ) trades at $0.04 with AI Score 51/100 (Grade B). Ligand Pharmaceuticals Incorporated is a biopharmaceutical company focused on developing and licensing biopharmaceutical assets. Market cap: $741,521, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for LGNYZ: LGNYZ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LGNYZ against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
LGNYZ: 4/7 perspectives are bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Ligand Pharmaceuticals Incorporated (LGNYZ) Healthcare & Pipeline Overview
Ligand Pharmaceuticals Incorporated develops and licenses biopharmaceutical assets, focusing on treatments for multiple myeloma, leukemia, and osteoporosis. With a high gross margin of 97.5% and a P/E ratio of 37.2, the company leverages strategic alliances with industry giants like Amgen, Merck, and Pfizer to drive growth in the pharmaceutical sector.
What Is the Investment Thesis for LGNYZ?
Ligand Pharmaceuticals Incorporated presents a compelling investment case based on its diversified portfolio of licensed biopharmaceutical assets and strategic partnerships. The company's high gross margin of 97.5% indicates efficient operations and strong pricing power. Growth catalysts include the continued expansion of its partnered programs, such as Kyprolis and Rylaze, and the potential approval of new indications for existing drugs like Filspari. The company's Captisol technology also provides a steady revenue stream. However, investors should be aware of risks associated with reliance on partners for drug development and commercialization, as well as potential regulatory hurdles and competition from other pharmaceutical companies. With a P/E ratio of 37.2, the company's valuation reflects its growth prospects and profitability.
Based on FMP financials and quantitative analysis
LGNYZ Key Highlights
- Gross Margin of 97.5% demonstrates strong operational efficiency and pricing power.
- Profit Margin of 46.4% indicates effective cost management and profitability.
- Strategic alliances with major pharmaceutical companies like Amgen, Merck, and Pfizer provide access to resources and expertise.
- Diverse portfolio of licensed biopharmaceutical assets reduces reliance on any single product.
- Captisol technology provides a consistent revenue stream and supports drug development efforts.
Who Are LGNYZ's Competitors?
LGNYZ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $4.88 | -5.97% | $1.80B | 68 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $309.46 | +3.97% | $33.07B | 61 |
| NEUP Neuphoria Therapeutics Inc. | $3.44 | +1.78% | $18.59M | 60 |
| RNTX Rein Therapeutics, Inc. | $1.01 | +2.37% | $28.38M | 51 |
| CSMYF COSMOS Pharmaceutical Corporation | $37.06 | +0.00% | $2.94B | 52 |
| LFLY Leafly Holdings, Inc. | $37.00 | +0.00% | $114.90M | 50 |
| GEDSF Gedeon Richter PLC | $25.95 | +4.43% | $4.75B | 53 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LGNYZ's Key Strengths?
- Diversified portfolio of licensed biopharmaceutical assets.
- Strategic alliances with major pharmaceutical companies.
- Proprietary Captisol technology.
- High gross margin.
What Are LGNYZ's Weaknesses?
- Reliance on partners for drug development and commercialization.
- Dependence on regulatory approvals for partnered products.
- Potential competition from other pharmaceutical companies.
- Limited control over the commercial success of licensed products.
What Could Drive LGNYZ Stock Higher?
- Continued expansion of partnered programs, such as Kyprolis and Rylaze.
- Potential approval of new indications for existing drugs like Filspari.
- Revenue generation from Captisol technology sales.
- Potential for new licensing agreements with pharmaceutical companies.
- Advancements in clinical trials for partnered drug candidates.
What Are the Key Risks for LGNYZ?
- Financial-distress signal — its Altman Z-Score of 1.67 sits in the distress zone (elevated bankruptcy risk).
- Rich valuation — a P/E of 37.2 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Reliance on partners for drug development and commercialization.
- Regulatory hurdles and delays in drug approvals.
- Competition from other pharmaceutical companies.
- Patent expirations on licensed products.
- Pricing pressures and reimbursement challenges.
What Are the Growth Opportunities for LGNYZ?
- Expansion of Captisol Applications: Ligand's Captisol technology is used to improve the solubility and stability of various drugs. Expanding the applications of Captisol to new drug formulations and therapeutic areas represents a significant growth opportunity. The global market for drug delivery technologies is projected to reach billions of dollars by 2028, driven by the increasing demand for improved drug efficacy and patient compliance. Ligand can leverage its expertise in Captisol chemistry to capture a larger share of this market.
- Development of New Drug Candidates: Ligand can invest in the development of new drug candidates to expand its portfolio of licensable assets. Focusing on therapeutic areas with unmet medical needs, such as oncology, immunology, and neurology, can increase the potential for successful drug development and commercialization. The global market for new drug development is expected to grow, driven by advancements in biotechnology and personalized medicine. Ligand can leverage its drug discovery and development capabilities to create valuable assets for licensing.
- Geographic Expansion: Ligand can expand its geographic presence by establishing partnerships and licensing agreements in new markets. Emerging markets, such as China and India, offer significant growth opportunities due to their large populations and increasing healthcare spending. The global pharmaceuticals market is increasingly shifting towards emerging markets, driven by economic growth and improved access to healthcare. Ligand can leverage its licensing model to enter these markets without significant capital investment.
- Strategic Acquisitions: Ligand can pursue strategic acquisitions to acquire complementary technologies, products, and expertise. Acquiring companies with established drug development platforms or commercialized products can accelerate Ligand's growth and diversification. The biopharmaceutical industry is characterized by frequent mergers and acquisitions, as companies seek to expand their portfolios and capabilities. Ligand can leverage its financial resources and expertise to identify and acquire attractive targets.
- Advancing Filspari for Rare Kidney Diseases: Filspari, a dual endothelin and angiotensin II receptor antagonist, is in development for rare kidney diseases. Successful development and commercialization of Filspari could generate significant revenue for Ligand through milestone payments and royalties. The market for rare kidney disease treatments is growing, driven by increased awareness and improved diagnostic capabilities. Ligand can leverage its expertise in drug development and regulatory affairs to advance Filspari through clinical trials and regulatory approval.
What Opportunities Does LGNYZ Have?
- Expansion of Captisol applications.
- Development of new drug candidates.
- Geographic expansion into emerging markets.
- Strategic acquisitions of complementary technologies and products.
What Threats Does LGNYZ Face?
- Patent expirations on licensed products.
- Regulatory hurdles and delays.
- Pricing pressures and reimbursement challenges.
- Competition from generic drugs and biosimilars.
What Are LGNYZ's Competitive Advantages?
- Intellectual property protection on drug candidates and technologies.
- Established relationships with major pharmaceutical companies.
- Expertise in drug development and licensing.
- Proprietary Captisol technology.
What Does LGNYZ Do?
Ligand Pharmaceuticals Incorporated, founded in 1987 and based in Jupiter, Florida, is a biopharmaceutical company engaged in the development and licensing of biopharmaceutical assets globally. The company's business model centers around creating and acquiring promising drug candidates and then licensing them to larger pharmaceutical companies for further development and commercialization. Ligand's portfolio includes a range of commercial programs such as Kyprolis and Evomela for multiple myeloma, Rylaze for acute lymphoblastic leukemia, and Filspari for rare kidney diseases. They also offer Teriparatide injection for osteoporosis, Vaxneuvance for pneumococcal disease prevention, and Pneumosil, a pneumococcal conjugate vaccine. Ligand's diversified product offerings extend to treatments like TZIELD for delaying the onset of type 1 diabetes, Nexterone for cardiac arrhythmias, Zulresso for postpartum depression, and Veklury for COVID-19. Additionally, they provide Noxafil-IV, Duavee, Exemptia, Vivitra, Bryxta, and Zybev for various indications. The company collaborates with major pharmaceutical players like Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International through alliances, licenses, and other business relationships. Ligand also sells Captisol materials, a chemically modified cyclodextrin used to improve the solubility and stability of drugs. This broad portfolio and strategic partnership approach positions Ligand as a key player in the biopharmaceutical industry.
What Products and Services Does LGNYZ Offer?
- Develops and licenses biopharmaceutical assets.
- Offers treatments for multiple myeloma, leukemia, and osteoporosis.
- Provides vaccine components for pneumococcal disease prevention.
- Offers Captisol materials to improve drug solubility and stability.
- Collaborates with major pharmaceutical companies through alliances and licenses.
- Focuses on creating and acquiring promising drug candidates for licensing.
How Does LGNYZ Make Money?
- Develops or acquires drug candidates and technologies.
- Licenses these assets to larger pharmaceutical companies.
- Receives milestone payments and royalties on partnered products.
- Sells Captisol materials to pharmaceutical companies.
What Industry Does LGNYZ Operate In?
Ligand Pharmaceuticals Incorporated operates within the competitive biopharmaceutical industry, characterized by rapid innovation, stringent regulatory requirements, and high R&D costs. The market is driven by increasing demand for novel therapies and personalized medicine. Ligand's licensing model allows it to participate in the growth of the pharmaceutical market without bearing the full burden of drug development costs. The company competes with other biopharmaceutical companies, as well as pharmaceutical giants, for licensing opportunities and partnerships. The industry is also subject to pricing pressures and patent expirations, which can impact profitability. The global pharmaceuticals market is projected to reach trillions of dollars by 2026, offering substantial growth opportunities for companies like Ligand.
Who Are LGNYZ's Key Customers?
- Large pharmaceutical companies like Amgen, Merck, and Pfizer.
- Biopharmaceutical companies seeking to license drug candidates.
- Companies requiring Captisol materials for drug formulation.
Company Profile
Ligand Pharmaceuticals Incorporated operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Jupiter, US. The company is led by CEO Todd C. Davis.
F-Score 6/9Financial Health
Ligand Pharmaceuticals Incorporated's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.67 places it in the distress zone, a signal of elevated financial risk.
ROE 16%Key Financial Metrics
Return on equity for Ligand Pharmaceuticals Incorporated stands at 16.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 10.0%, showing how much profit it generates from its asset base. LGNYZ trades at a trailing price-to-earnings ratio of 37.19, above the Healthcare sector average of ~23x. Its free cash flow yield is 2.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 21.28 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.5%, the inverse of the P/E and a quick read on earnings relative to price.
LGNYZ Valuation & Market Position
With a 742K market cap, Ligand Pharmaceuticals Incorporated sits in the micro-cap segment of the market. Relative to its peer group, LGNYZ's quantitative score of 51/100 is roughly in line with the peer average of 61/100.
FY2026 estForward Outlook
Wall Street analysts project Ligand Pharmaceuticals Incorporated revenue of about $287.7M for fiscal 2026, with EPS near $9.06. The estimate reflects 8 contributing analysts.
Net buyingInsider Activity
The most recent 11 insider filings for Ligand Pharmaceuticals Incorporated break down as 5 sales and 6 purchases. On net that is roughly 11K shares acquired (about $474K) — insiders putting money in tends to read as conviction.
LGNYZ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Ligand's future prospects, indicating potential growth.
- Community sentiment has been increasingly positive, driven by recent advancements in their drug pipeline.
- Analysts note that Ligand's partnerships with major pharmaceutical companies enhance their market position and credibility.
- The recent focus on innovative therapies aligns with broader industry trends, positioning Ligand favorably for upcoming opportunities.
Bear Case
- Concerns over regulatory hurdles have surfaced, causing some investors to reassess their positions.
- Market perception has been cautious due to potential competition in the biotech sector, which could impact Ligand's market share.
- Recent earnings reports showed slower growth than expected, leading to skepticism among analysts and traders.
- Social sentiment has also seen some bearish comments regarding the sustainability of Ligand's current business model.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
LGNYZ Latest News
No recent news available for LGNYZ.
LGNYZ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LGNYZ.
Price Targets
Wall Street price target analysis for LGNYZ.
LGNYZ MoonshotScore
What does this score mean?
The MoonshotScore rates LGNYZ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Todd C. Davis
Unknown
Information about Todd C. Davis's background is not available in the provided context. Therefore, a detailed career history, education, previous roles, and credentials cannot be provided. Further research would be needed to compile a comprehensive biography.
Track Record: Information about Todd C. Davis's track record is not available in the provided context. Therefore, key achievements, strategic decisions, and company milestones under their leadership cannot be provided. Further research would be needed to assess their performance.
LGNYZ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Ligand Pharmaceuticals Incorporated (LGNYZ) may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB, or exchanges like NYSE or NASDAQ. Companies in this tier may have limited financial disclosure, making it harder for investors to assess their financial health and operational performance. This tier often includes companies with distressed financials, early-stage ventures, or those that choose not to comply with stricter listing standards. Investing in OTC Other stocks carries higher risks due to the lack of regulation and transparency compared to listed exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower liquidity can lead to difficulty in buying or selling shares.
- Higher price volatility due to less trading activity.
- Potential for fraud or manipulation is greater on the OTC market.
- Lack of regulatory oversight compared to listed exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Check for any red flags or warning signs, such as pending lawsuits or regulatory investigations.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- The company has been in operation since 1987.
- Ligand Pharmaceuticals Incorporated has partnerships with reputable pharmaceutical companies like Amgen, Merck, and Pfizer.
- The company has a diverse portfolio of licensed biopharmaceutical assets.
Common Questions About LGNYZ (Healthcare)
What does Ligand Pharmaceuticals Incorporated do?
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that focuses on developing and licensing a diverse portfolio of drug assets. Their business model revolves around partnering with larger pharmaceutical companies to advance their drug candidates through clinical trials and commercialization. Ligand generates revenue through milestone payments, royalties on sales of partnered products, and sales of its Captisol materials, which enhance the solubility and stability of other drugs. This approach allows Ligand to participate in the pharmaceutical market without bearing the full burden of drug development costs.
What are the main risks for LGNYZ?
Ligand Pharmaceuticals Incorporated faces several risks inherent to the biopharmaceutical industry. A primary risk is its reliance on partners for the development and commercialization of its drug candidates, as delays or failures by partners could negatively impact revenue. Regulatory hurdles and potential delays in drug approvals also pose a significant risk. Competition from other pharmaceutical companies and the potential for patent expirations on licensed products could erode market share and profitability. Additionally, pricing pressures and reimbursement challenges in the healthcare industry could impact revenue from partnered products.
What are the key factors to evaluate for LGNYZ?
Ligand Pharmaceuticals Incorporated (LGNYZ) holds an AI score of 51/100 (moderate). P/E: 37.2x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does LGNYZ data refresh on this page?
LGNYZ prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven LGNYZ's recent stock price performance?
Ligand Pharmaceuticals Incorporated (LGNYZ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified portfolio of licensed biopharmaceutical assets. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LGNYZ overvalued or undervalued right now?
Ligand Pharmaceuticals Incorporated (LGNYZ) trades at 37.2x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying LGNYZ?
Before investing in Ligand Pharmaceuticals Incorporated (LGNYZ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding LGNYZ to a portfolio?
Key strength of Ligand Pharmaceuticals Incorporated (LGNYZ): Diversified portfolio of licensed biopharmaceutical assets. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-18.
- AI analysis is pending and may provide further insights.
- OTC market data may be limited or less reliable than listed exchanges.